Societal CDMO Reports Second Quarter 2023 Financial Results
14 août 2023 16h05 HE
|
Societal CDMO, Inc.
Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement...
Societal CDMO Reschedules Second Quarter 2023 Financial Results Reporting to August 14, 2023
09 août 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023
02 août 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
11 juil. 2023 10h55 HE
|
The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...
Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate
10 juil. 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
06 juin 2023 09h30 HE
|
OKYO Pharma LTD
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06,...
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
25 mai 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
16 mai 2023 11h37 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
Societal CDMO to Participate in RBC Capital Markets Global Healthcare Conference
09 mai 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
Global Early Toxicity Testing Market to Generate USD 14.39 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
09 mai 2023 09h00 HE
|
Next Move Strategy Consulting
New York, May 09, 2023 (GLOBE NEWSWIRE) -- According to a report published by Next Move Strategy Consulting, the Early Toxicity Testing Market generated USD 8.92 billion in 2022, and is projected to...